What is Zacks Research’s Estimate for Omnicell Q4 Earnings?

Omnicell, Inc. (NASDAQ:OMCL) – Research analysts at Zacks Research raised their Q4 2024 earnings per share estimates for Omnicell in a research report issued to clients and investors on Thursday, January 2nd. Zacks Research analyst R. Department now expects that the company will earn $0.29 per share for the quarter, up from their prior forecast of $0.28. The consensus estimate for Omnicell’s current full-year earnings is $0.93 per share. Zacks Research also issued estimates for Omnicell’s Q1 2025 earnings at $0.16 EPS, Q2 2025 earnings at $0.19 EPS and FY2026 earnings at $1.01 EPS.

Several other equities analysts have also recently weighed in on the stock. JPMorgan Chase & Co. raised their price target on shares of Omnicell from $37.00 to $44.00 and gave the company a “neutral” rating in a research report on Thursday, November 21st. Bank of America lowered their price target on Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a research report on Monday. Wells Fargo & Company lifted their price objective on shares of Omnicell from $30.00 to $41.00 and gave the stock an “equal weight” rating in a report on Monday, October 14th. Craig Hallum increased their target price on shares of Omnicell from $45.00 to $64.00 and gave the company a “buy” rating in a report on Thursday, October 31st. Finally, StockNews.com lowered shares of Omnicell from a “buy” rating to a “hold” rating in a research report on Tuesday, December 10th. Five analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $50.17.

Omnicell Trading Down 1.3 %

Shares of OMCL stock opened at $44.71 on Monday. The firm has a fifty day simple moving average of $46.17 and a two-hundred day simple moving average of $40.65. Omnicell has a 12 month low of $25.12 and a 12 month high of $55.74. The firm has a market capitalization of $2.07 billion, a PE ratio of -114.64, a price-to-earnings-growth ratio of 34.96 and a beta of 0.78.

Insider Transactions at Omnicell

In related news, Director Mark W. Parrish sold 12,000 shares of the business’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $47.30, for a total transaction of $567,600.00. Following the sale, the director now directly owns 58,427 shares in the company, valued at approximately $2,763,597.10. The trade was a 17.04 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 2.64% of the company’s stock.

Hedge Funds Weigh In On Omnicell

Several hedge funds have recently bought and sold shares of the company. Victory Capital Management Inc. boosted its holdings in Omnicell by 11,982.3% in the 3rd quarter. Victory Capital Management Inc. now owns 1,148,426 shares of the company’s stock valued at $50,071,000 after purchasing an additional 1,138,921 shares during the period. Federated Hermes Inc. grew its position in Omnicell by 1,113.6% during the second quarter. Federated Hermes Inc. now owns 991,151 shares of the company’s stock worth $26,830,000 after buying an additional 909,480 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. purchased a new position in Omnicell during the third quarter worth about $32,721,000. Pacer Advisors Inc. increased its stake in Omnicell by 32.6% in the 2nd quarter. Pacer Advisors Inc. now owns 2,070,434 shares of the company’s stock worth $56,047,000 after acquiring an additional 508,789 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of Omnicell by 750.5% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 294,037 shares of the company’s stock valued at $12,820,000 after acquiring an additional 259,463 shares during the last quarter. Hedge funds and other institutional investors own 97.70% of the company’s stock.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.